Genix.ai Launches PhD-Led Biocompute Services to Accelerate Drug Discovery for Pharma R&D

BANGALORE, India - June 12, 2026 - PRLog -- BENGALURU, India — Genix.ai, India's AI-native genomics company, today announced the availability of its Biocompute service portfolio — a comprehensive suite of computational biology services purpose-built for pharmaceutical and biotechnology R&D teams. The offering encompasses molecular docking and structure-based drug design, custom bioinformatics pipeline development, NGS data analysis, and multi-omics biomarker discovery, all delivered under NDA with publication-ready outputs and turnaround times as fast as 48 hours. As drug discovery timelines lengthen and R&D budgets face increasing scrutiny.

Molecular Docking & Computer-Aided Drug Design (CADD)

At the core of Genix.ai's drug discovery support is a full Computer-Aided Drug Design (CADD) pipeline via its Molecular Docking service, enabling pharma teams to identify, screen, and optimise drug candidates computationally before committing resources to wet-lab validation. The service includes:

• Protein structure prediction using AlphaFold3 and RoseTTAFold for targets without solved crystal structures
• Virtual screening campaigns to evaluate large compound libraries against binding sites of interest
• Homology modelling for structurally uncharacterised drug targets
• Molecular dynamics (MD) simulations using GROMACS to assess binding stability, conformational changes, and binding free energy
• ADMET prediction profiling for absorption, distribution, metabolism, excretion, and toxicity — critical for early-stage lead optimisation
• Full interaction maps, binding pose visualisations, and docking score reports, delivered in publication-ready format

Molecular docking campaigns (https://bit.ly/43p7liT) are priced from USD 1,000 per target with a 5–10 day standard turnaround, making them accessible even for early-stage drug discovery programmes and academic-pharma collaborations.

Bioinformatics Tools & NGS Data Analysis

Genix.ai's bioinformatics analysis stack supports the full spectrum of next-generation sequencing (NGS) data types commonly used in pharma research, including whole-genome sequencing (WGS), whole-exome sequencing (WES), bulk RNA-Seq, single-cell RNA-Seq (scRNA-Seq), ChIP-Seq, ATAC-Seq, and metagenomics. The team works across the following industry-standard tools and pipelines:

• GATK for variant calling and germline/somatic mutation analysis
• STAR and BWA-MEM2 for alignment of short-read sequencing data
• DESeq2 and Salmon for differential expression analysis and transcript quantification
• Seurat and Scanpy for single-cell RNA-Seq clustering, trajectory analysis, and cell type annotation
• RDKit and AutoDock Vina for cheminformatics and molecular property calculations
• ClinVar and gnomAD for variant annotation and population-level interpretation

All analyses are conducted using validated, reproducible pipelines with full QC documentation, methods sections suitable for regulatory or publication submission, and raw analysis files including VCF, BAM, and count matrices as appropriate.

Media & Partnership Enquiries

Website: https://genix.ai/biocompute/
Email:  biocompute@genix.ai
Phone / WhatsApp:  +91 886 141 4344